Patient access scheme swings NICE yes for Amgen's Nplate?
This article was originally published in Scrip
Executive Summary
In a change of heart, NICE, the health technology appraisal body for England and Wales, says it will recommend Amgen's thrombopoietin receptor agonist Nplate (romiplostim) for some patients with chronic idiopathic thrombocytopenic purpura (ITP). The turnaround comes after Amgen submitted a revised economic model and a patient access scheme to the institute.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.